Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy

NCT05824390 is registered in ClinicalTrials.gov with XIEJINGYUAN as lead sponsor.

NCT NCT05824390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05824390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy
Lead sponsor
XIEJINGYUAN
Phase
Phase 4
Overall status
Unknown status
Start date
June 20, 2020
Completion date
October 1, 2023
Enrollment
116 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

iga nephropathy